{"id":102,"date":"2010-02-24T12:24:27","date_gmt":"2010-02-24T11:24:27","guid":{"rendered":"https:\/\/blogs.bmj.com\/heart-journalscan\/?p=102"},"modified":"2015-11-12T13:51:17","modified_gmt":"2015-11-12T12:51:17","slug":"high-dose-arbs-maximise-benefits-in-heart-failure","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/","title":{"rendered":"High dose ARBs maximise benefits in heart failure"},"content":{"rendered":"<p>Several studies have determined the efficacy of angiotensin-receptor blockers (ARBs) for treating heart failure. However, the relationship between high and low doses and clinical outcomes has been poorly studied to date.<!--more--><br \/>\nIn this large double-blind study undertaken in 255 centres across 30 countries, 3846 patients with NYHA heart failure class II-IV, a left-ventricular ejection fraction of 40% or less, and intolerance to ACE inhibitors were randomly assigned to either losartan 150mg od (n=1927) or 50mg daily (n=1919). The primary endpoint was death or admission for heart failure. Analysis was by intention to treat.<br \/>\nThe median follow-up in each group was 4.7 years. 828 (43%) of patients in the 150mg group versus 889 (46%) in the 50mg group died or were admitted for heart failure (hazard ratio 0.90; p=0.027). For the two primary endpoint components, no difference was seen in deaths (635 patients in the 150mg group vs. 665, hazard ratio 0.94; p=0.24), however 450 versus 503 patients were admitted for heart failure (hazard ratio 0.87; p=0.025). However, renal impairment, hypotension, and hyperkalaemia were more common in the 150mg group, but did not lead to significantly more treatment discontinuations.<br \/>\nConclusions:<br \/>\nLosartan 150mg, as compared to a 50mg dose, reduced the rate of death or admission for heart failure in patients with heart failure, reduced ejection fraction, and intolerance to ACE inhibitors. ARB doses can be uptitrated for clinical benefit in patients with impaired ventricular function.<br \/>\n\u2022 Konstam MA, Neaton JD, Dickstein K et al. Effect of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-1848.<\/p>\n<p>Figure 1: Kaplan-Meier curves for patients given 50mg vs 150mg losartan<br \/>\n<a href=\"http:\/\/heart.bmj.com\/site\/misc\/April2.pdf\">http:\/\/heart.bmj.com\/site\/misc\/April2.pdf<\/a><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Several studies have determined the efficacy of angiotensin-receptor blockers (ARBs) for treating heart failure. However, the relationship between high and low doses and clinical outcomes has been poorly studied to date. [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":103,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[279],"tags":[],"class_list":["post-102","post","type-post","status-publish","format-standard","hentry","category-general-cardiology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>High dose ARBs maximise benefits in heart failure - Heart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"High dose ARBs maximise benefits in heart failure - Heart\" \/>\n<meta property=\"og:description\" content=\"Several studies have determined the efficacy of angiotensin-receptor blockers (ARBs) for treating heart failure. However, the relationship between high and low doses and clinical outcomes has been poorly studied to date. [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"Heart\" \/>\n<meta property=\"article:published_time\" content=\"2010-02-24T11:24:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-11-12T12:51:17+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"High dose ARBs maximise benefits in heart failure\",\"datePublished\":\"2010-02-24T11:24:27+00:00\",\"dateModified\":\"2015-11-12T12:51:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/\"},\"wordCount\":274,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"articleSection\":[\"General cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/\",\"name\":\"High dose ARBs maximise benefits in heart failure - Heart\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\"},\"datePublished\":\"2010-02-24T11:24:27+00:00\",\"dateModified\":\"2015-11-12T12:51:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2010\\\/02\\\/24\\\/high-dose-arbs-maximise-benefits-in-heart-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"High dose ARBs maximise benefits in heart failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"name\":\"Heart\",\"description\":\"Highlighted articles from non-cardiological journals relevant to cardiology\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\",\"name\":\"Heart\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"width\":145,\"height\":34,\"caption\":\"Heart\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"High dose ARBs maximise benefits in heart failure - Heart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/","og_locale":"en_US","og_type":"article","og_title":"High dose ARBs maximise benefits in heart failure - Heart","og_description":"Several studies have determined the efficacy of angiotensin-receptor blockers (ARBs) for treating heart failure. However, the relationship between high and low doses and clinical outcomes has been poorly studied to date. [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/","og_site_name":"Heart","article_published_time":"2010-02-24T11:24:27+00:00","article_modified_time":"2015-11-12T12:51:17+00:00","twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/"},"author":{"name":"","@id":""},"headline":"High dose ARBs maximise benefits in heart failure","datePublished":"2010-02-24T11:24:27+00:00","dateModified":"2015-11-12T12:51:17+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/"},"wordCount":274,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"articleSection":["General cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/","url":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/","name":"High dose ARBs maximise benefits in heart failure - Heart","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/#website"},"datePublished":"2010-02-24T11:24:27+00:00","dateModified":"2015-11-12T12:51:17+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/heart\/2010\/02\/24\/high-dose-arbs-maximise-benefits-in-heart-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/heart\/"},{"@type":"ListItem","position":2,"name":"High dose ARBs maximise benefits in heart failure"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/heart\/#website","url":"https:\/\/blogs.bmj.com\/heart\/","name":"Heart","description":"Highlighted articles from non-cardiological journals relevant to cardiology","publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/heart\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/heart\/#organization","name":"Heart","url":"https:\/\/blogs.bmj.com\/heart\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","contentUrl":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","width":145,"height":34,"caption":"Heart"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/heart\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/users\/103"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/comments?post=102"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/102\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/media?parent=102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/categories?post=102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/tags?post=102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}